scroll
LEARN MORE
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
ASX.IMU $0.11
20 MINUTE DELAYED
ANALYSIS
OPINION
ACTION
i
PERFORMANCE
i
SHARE PRICE ACTIVITY | |
---|---|
Last (Price) | 0.11 |
Change | 0.00 (0.00) |
Bid / Ask | 0.12 - 0.10 |
Volume | 0 |
Volume (3mths avg) | 0 |
Turnover | 0 |
Open | 0.00 |
Day Range | 0.11 - 0.12 |
VWAP | 0.00 |
Prev Close | 0.11 |
Last Trade | 01/12 8:14am (AEST) |
i
KEY INFORMATION | |
---|---|
Sector | Healthcare |
Shares Issued | 6,212,708,776 |
NTA/Share | 0.00 |
Last Dividend | 0.00 |
Dividend Ex Date | 0 |
Dividend Pay Date | 29 MAR 2006 |
i
CURRENT () | |
---|---|
Revenue | 0.00 |
EBITDA | -35.53 |
Profit | -37.87 |
Earnings Per Share (EPS) | 0 |
Dividend Per Share (DPS) | 0 |
Yield % | 0.00 |
Market Cap | 0 |
Price to Earnings Ratio (P/E) | 0 |
i
TARGET PRICE FORECAST
i
ESTIMATES () | |
---|---|
Revenue | 2.93 |
EBITDA | -51.68 |
Profit | -47.65 |
Earnings Per Share (EPS) | -0.01 |
Dividend Per Share (DPS) | 0.00 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
0.00
Lt Growth Rate
0.00
Recommendation (BUY)
2.00
ACTION
IMU
UPDATED
01/09/2023 08:55
MM likes what IMU are trying to achieve, but it’s hard to be bullish on this volatile stock
Add To Hit List
IMU
UPDATED
07/06/2022 17:40
MM is neutral IMU – one for a high risk punt ~17c for the brave using stops below 15c
Add To Hit List
IMU
UPDATED
22/03/2022 23:08
Business Summary
Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.Relevant suggested news and content from the site
Only available to Members
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing.
Click here